Evan Diamond is an associate in the Intellectual Property practice of Paul Hastings in the New York office. Mr. Diamond focuses his practice on patent litigation matters, particularly in the fields of pharmaceuticals and biotechnology.
Mr. Diamond has been a member of trial teams that obtained favorable settlements for branded pharmaceutical clients in Hatch-Waxman litigations over multi-billion dollar pharmaceutical products, including anti-depressants and Alzheimer's disease treatments. Mr. Diamond was also a member of the trial team that recently obtained a preliminary injunction from the District of Delaware, preventing the launch of a generic dermatological drug product. Mr. Diamond has also conducted in-depth pre-suit investigations for complex branded pharmaceutical products, including respiratory products. In addition, Mr. Diamond has consulted regarding patents in a range of biotechnology fields, including nucleotide analogues, protein-based therapeutics and industrial enzymes.
Mr. Diamond received his J.D. from Harvard Law School, cum laude, in 2007 where he served as Executive Technical Editor of the Harvard Journal on Legislation. He graduated with a B.A. in Biochemistry from University of Pennsylvania, summa cum laude, and a M.S. in Chemistry in 2004.